Alpha‐Gal Sensitization Dynamics in Individuals After Tick Bites With or Without Erythema Migrans
Clinical & Experimental Allergy · 2025
DOI: 10.1111/cea.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2025. Verfasst von Tamara van Gorkom und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Immunology, Diakonessenhuis Hospital, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Tick Bites, Erythema Chronicum Migrans, Allergens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Welfare and Sport of the Netherlands.
Abstract (Originalsprache)
α‐Gal syndrome (AGS) is an emerging tick‐borne disease characterised by the development of specific immunoglobulin E (sIgE) antibodies against galactose‐α‐1,3‐galactose (α‐gal), a carbohydrate found in most mammalian species, but not in humans. AGS occurs in individuals with a history of tick bites. Currently, no data exist on α‐gal sIgE seroprevalence in the Dutch population, including those with tick bites or erythema migrans (EM). Therefore, this study aimed to determine the rate of α‐gal sIgE seroprevalence in the Dutch population, to assess α‐gal sIgE seroconversion after tick bites, and to determine the relationship between EM and α‐gal sIgE in serum. α‐Gal sensitisation rates were assessed in individuals with tick bites (TB), EM, and the general population. Blood samples were collected from TB‐ and EM‐cases at baseline and again after 3 months. Single blood samples from controls were selected from a Dutch population survey. In total, 156 TB‐cases, 160 EM‐cases, and 316 population controls were included. α‐Gal sensitisation rates were 1.9% for population controls and 10.3% and 19.1% for TB‐ and EM‐cases at baseline, respectively (cut‐off α‐gal sIgE: ≥ 0.10 kU A /L). Rates increased to 17.9% for TB‐cases, comparable to the 16.9% for EM‐cases 3 months after EM‐development. Distinct α‐gal sensitisation rates were observed between TB‐ and EM‐cases over a 3‐month period. TB‐cases showed a rising rate, while EM‐cases had elevated rates at both time points. This difference is likely due to timing of the tick bite, with TB‐cases having a recent bite and EM‐cases developing EM days to weeks post‐bite. Both groups had higher sensitisation rates than population controls, corroborating the link between tick bites and α‐gal sensitisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology and Immunology, Diakonessenhuis Hospital, Utrecht, the Netherlands.
- Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
- Department of Internal Medicine, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
ORCID-Profile: Tamara van Gorkom, Michiel Heron
Förderung
- Ministry of Health, Welfare and Sport of the Netherlands
Zitieren
APA
van Gorkom, T., Heron, M., Hofhuis, A., Jongerius, C., van der Klis, F. R. M., Oude Elberink, H. N. G., Sprong, H., Thijsen, S. F. T., & Kremer, K. (2025). Alpha‐Gal Sensitization Dynamics in Individuals After Tick Bites With or Without Erythema Migrans. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70011
Vancouver
van Gorkom T, Heron M, Hofhuis A, Jongerius C, van der Klis FRM, Oude Elberink HNG, et al. Alpha‐Gal Sensitization Dynamics in Individuals After Tick Bites With or Without Erythema Migrans. Clinical & Experimental Allergy. 2025. doi:10.1111/cea.70011
BibTeX
@article{vanGorkom2025,
author = {van Gorkom, Tamara and Heron, Michiel and Hofhuis, Agnetha and Jongerius, Carlijn and van der Klis, Fiona R M and Oude Elberink, Hanneke N G and Sprong, Hein and Thijsen, Steven F T and Kremer, Kristin},
title = {Alpha‐Gal Sensitization Dynamics in Individuals After Tick Bites With or Without Erythema Migrans},
journal = {Clinical & Experimental Allergy},
year = {2025},
doi = {10.1111/cea.70011}
}
EUVIMED